David Taggart

Showing 1-12 of 12 articles

Prognostic performance of the Society of Thoracic Surgeons risk score in patients with left main coronary artery disease undergoing revascularisation: a post hoc analysis of the EXCEL trial

Thuijs D, Habib R, Head S, Puskas J, Taggart D, Stone G, Zhang Z, Serruys P, Sabik J, Kappetein A

May 20, 2020 | 10.4244/EIJ-D-19-00417

FFR for CABG: not ready for prime time

Gaudino M, Di Franco A, Taggart D

December 6, 2019 | 10.4244/EIJV15I11A177

Does an occluded RCA affect prognosis in patients undergoing PCI or CABG for left main coronary artery disease? Analysis from the EXCEL trial

Chen S, Karmpaliotis D, Redfors B, Shlofmitz E, Ben-Yehuda O, Crowley A, Mehdipoor G, Puskas J, Kandzari D, Banning A, Morice M, Taggart D, Sabik J, Serruys P, Kappetein A, Stone G

August 9, 2019 | 10.4244/EIJ-D-19-00263

Absence of proof or proof of absence? The risk of underpowered studies in cardiovascular medicine

Gaudino M, Benedetto U, Taggart D

September 20, 2018 | 10.4244/EIJV14I7A126

What is new in the armamentarium of coronary surgeons to compete with PCI?

Gaudino M, Taggart D

July 20, 2018 | 10.4244/EIJV14I4A69

Coronary interventions

Design and rationale for a randomised comparison of everolimus-eluting stents and coronary artery bypass graft surgery in selected patients with left main coronary artery disease: the EXCEL trial

Kappetein AP, Serruys P, Sabik J, Leon M, Taggart D, Morice M, Gersh B, Pocock S, Cohen D, Wallentin L, Ben-Yehuda O, Van Es G-A, Simonton C, Stone G

September 18, 2016 | 10.4244/EIJV12I7A141

Coronary interventions

Rationale and design of the SYNTAX II trial evaluating the short to long-term outcomes of state-of-the-art percutaneous coronary revascularisation in patients with de novo three-vessel disease

Escaned J, Banning A, Farooq V, Echavarría-Pinto M, Onuma Y, Ryan N, Cavalcante R, Campos C, Stanetic B, Ishibashi Y, Suwannasom P, Kappetein AP, Taggart D, Morel M, Van Es G-A, Serruys P

June 10, 2016 | 10.4244/EIJV12I2A36

2014 ESC/EACTS Guidelines on myocardial revascularization

Windecker S, Kolh P, Alfonso F, Collet J-P, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann F, Richter D, Schauerte P, Uva M, Stefanini G, Taggart D, Torracca L, Valgimigli M, Wijns W, Witkowski A

January 22, 2015 | 10.4244/EIJY14M09_01

Numbers needed to treat (lives!) and numbers needed to save (money)

Ribichini F, Taggart D, Vassanelli C

June 28, 2013 | 10.4244/EIJV9I2A28

Does a hybrid approach to multivessel revascularisation really make sense?

Taggart D

March 22, 2013 | 10.4244/EIJV8I11A189

Does prior PCI influence the clinical outcome of CABG?

Taggart D

May 19, 2009

Drug eluting stents in left main stem stenosis: patients will pay the price

Taggart D

February 20, 2007

Latest news

NEW ISSUE

CTOs, next-day discharge after TAVI, ViV, cerebral embolic protection, TMVR

August 7, 2020

NEW

Ahead of Print: Coronary Artery Thrombosis in COVID-19

August 7, 2020

Editorial

Coronary collaterals, the natural grafts of CTO lesions

C. Di Mario

August 7, 2020

TICAKOREA, PEPCAD NSTEMI, CROSS-AMI, PARTNER-2A 5 years, and more

(The Trials book is supported by Biotronik)

August 5, 2020

Guidance Papers

Guidelines, consensus & position papers

June 25, 2020

Editorial

Intravascular ultrasound in PCI for in-stent CTO: guidance for long-term success

JM De la Torre Hernandez

August 7, 2020

JAA

This Week's JAA's: Real-world Use of the Evolut PRO Valve...